News round-up for 26-30 June by DDW Digital Content Editor Diana Spencer.
This week we have heard about a number of studies that demonstrate an inventive solution to an old problem, either through the use of an original approach or new, advanced technology.
Whether it be a monoclonal antibody to treat peanut allergy, or using artificial intelligence (AI) to identify influenza drug targets, each discovery reflects the level of scientific innovation and diversity of approaches being employed in drug development today.
The top stories:
IgGenix has made advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies. The company’s research data was presented during the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress, in Hamburg, Germany.
Scientists from Japan have identified regulator CD69, which controls the differentiation of CD8+ T cells within tumour-draining lymph nodes, thereby regulating anti-tumour immunity.
Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, has unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate.
Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, has announced a breakthrough in its influenza AI Programme with CytoReason.
A new study has revealed consistent biological signals in the human microbiome and other physiological signals associated with autism. The research highlights the need for long-term studies to determine autism’s underlying causes.